Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Glomerulonephritis Clinical Trials

A listing of Glomerulonephritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (24) clinical trials

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for ...

Phase

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

The purpose of this Phase IIa/IIb dose ranging study is to generate human data in the intended patient population with IgAN to establish clinical proof-of-concept and to evaluate dose responses to support dose selection for subsequent clinical development of LNP023 for IgAN and potentially other indications

Phase

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies

Phase

Study of RG-012 in Male Subjects With Alport Syndrome

This is a randomized, double-blind, placebo-controlled, multi-center, Phase 2 study of RG-012 in male subjects with Alport syndrome. Eligible subjects will be randomized in a 1:1 ratio to receive subcutaneous (SC) injections of RG-012 or placebo every other week for 48 weeks. After completion of this double-blind treatment period, subjects ...

Phase

ACE-inhibitors in Extracapillary Glomerulonephritis

The natural course of extracapillary glomerulonephritis is severe leading to End-Stage Renal Disease (ESRD) or death in most cases. Despite immunosuppressive treatment, long-term renal outcome remains poor since active crescents usually progress to fibrotic scars with glomerular occlusion and disruption.In experimental models Angiotensin Converting Enzyme (ACE)-inhibitor therapy targeting the over-expression ...

Phase

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

This is a pilot intervention study to evaluate preliminary evidence of the safety and effectiveness of a novel combination immunosuppressive regimen, Rituximab plus cyclosporine, in the treatment of idiopathic membranous nephropathy. Membranous nephropathy is a condition that affects the kidney and involves damage to the walls of tiny blood vessels ...

Phase

A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN

The primary objective of this study is to determine whether ACH-0144471 can increase blood C3 levels in participants with low C3 levels due to either C3G or IC-MPGN.

Phase

Daratumumab in Treatment of PGNMID and C3 GN

This study is an open-label phase 2 trial of the safety and efficacy of daratumumab, in the treatment of PGNMID and C3GN associated with monoclonal gammopathy. Subjects will be screened at outpatient Nephrology Clinic visit appointments and interested qualified subjects will be consented and offered participation in this trial. Once ...

Phase

The Iguratimod Effect on Lupus Nephritis (IGeLU)

This study is a 52-week, randomized, open, active-controlled trial of patients with active diffused lupus nephritis, to assess the efficacy and safety of a novel chemical synthetic agent iguratimod. The subjects will randomly receive iguratimod or cyclophosphamide followed with azathioprine, both combined with steroids.

Phase

An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES)

This is an Open-Label Phase 2 Study to Evaluate the Efficacy and Safety of IdeS in anti-GBM disease (Goodpasture's disease, i.e. GP) with Adverse Renal Prognosis. The primary efficacy objective is to evaluate the efficacy of an IdeS based regimen to salvage independent renal function measured as no need for ...

Phase